Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Biora will present preclinical data from the BioJet™ Systemic Oral Delivery Platform at the conference on June 19, 2024.
Four device performance studies demonstrate the NaviCap platform's ability to deliver therapeutics directly to the colon under variable GI conditions.
Management will host conference call and webcast today, May 15, 2024, at 4:30 PM Eastern / 1:30 PM Pacific.
The company's management will host a webcast and conference call on Wednesday, May 15, 2024, after the close of financial markets.
Results of human device function studies for the NaviCap„ Targeted Oral Delivery Platform in healthy volunteers and patients with UC
Dosing of all patients in the trial has been successfully completed; final results are expected to be available in late Q2 2024.
Patent claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal tract.
All pharmacokinetic endpoints were achieved; all NaviCap„ devices performed as intended; no safety signals observed